Abstract
Background
Chronic hepatitis C virus (HCV) infection is an important public health issue owing to its worldwide prevalence and its profound effects on patients’ well-being and function. We developed a new patient self-report tool, the HCV patient-reported outcomes (HCV-PRO) instrument, to assess patients’ function and well-being reflecting both HCV disease and treatment burdens.
Methods
Items were developed through a qualitative phase including scientific literature review, expert appraisal, and semi-structured patient interviews. The item pool was initially psychometrically tested in 60 adult HCV patients, 18 years of age or older at a university hepatology clinic. A final psychometric test was conducted in 241 members of the online Harris International Panel to examine scale reliability, confirm factor structure, and assess convergent and discriminant validity.
Results
A single-factor 16-item HCV-PRO instrument demonstrated good model fit. The HCV-PRO items and total score (range 0–100) showed excellent item response (few floor and ceiling effects) and reliability (alpha > 0.90). Convergent validity was established from moderate to high (r > 0.50) correlation with symptom burden, life satisfaction (ladder of life), and SF-36v2 scales scores. Mean HCV-PRO scores differentiated between currently treated patients, those previously treated, and patients never treated (p < 0.01), suggesting strong known-groups validity.
Conclusions
The results provide initial evidence that the HCV-PRO can yield reliable and valid measurement of the effects of HCV and its treatment on the well-being and function of HCV-infected patients.
Similar content being viewed by others
References
World Health Organization. (2012). Hepatitis C. Fact Sheet N°164. Geneva, Switzerland: World Health Organization. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 17 Sept, 2012.
Davis, G. L., Alter, M. J., El-Serag, H., Poynard, T., & Jennings, L. W. (2010). Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology, 138, 513–521.
Ware, J. E, Jr, Bayliss, M. S., Mannocchia, M., & Davis, G. L. (1999). Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The Interventional Therapy Group. Hepatology, 30, 550–555.
Bayliss, M. S., Gandek, B., Bungay, K. M., Sugano, D., Hsu, M. A., & Ware, J. E, Jr. (1998). A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Quality of Life Research, 7, 39–55.
Gremion, C., & Cerny, A. (2005). Hepatits C virus and the immune system: A concise review. Reviews in Medical Virology, 15, 235–268.
Hsu, P., & Federico, C. A. (2012). Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. Journal of Gastroenterology and Hepatology, 27, 149–157.
Younossi, Z., Kallman, J., & Kincaid, J. (2007). The effects of HCV infection and management on health-related quality of life. Hepatology, 45, 806–816.
Smith, B. D., Morgan, R. L., Beckett, G. A., et al. (2012). Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recommendations and Reports 61(No. RR-4): 1–36.
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009). Diagnosis, management, and treatment of hepatitis C: An update. Hepatology, 49, 1335–1374.
National Institutes of Health. (2002). National institutes of health consensus development conference statement. Management of hepatitis C: 2002. NIH Consensus Development Program. http://consensus.nih.gov/2002/2002hepatitisc2002116html.htm. Accessed 20 Sept 2012.
Modi, A. A., & Liang, T. J. (2008). Hepatitis C: A clinical review. Oral Diseases, 14(1), 10–14.
Siebert, U., & Sroczynski, G. (2005). Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German federal ministry of health and social security. International Journal of Technology Assessment in Health Care, 21(1), 55–65.
Younossi, Z. M., Aggarwal, J., Martin, M., et al. (2012). Health-related quality-of-life among genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment: Post hoc analyses of data from the ADVANCE trial. Journal of Hepatology, 56(Suppl 2), S462–S463.
Younossi, Z. M., Aggarwal, J., Martin, M., et al. (2012b). Health-related quality-of-life among genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment: Post hoc analyses of data from the ADVANCE trial. Gastroenterology 142(Suppl 5): S-955. [Abstract Sa1048].
Welsch, C., Jesudian, A., Zeuzem, S., & Jacobson, I. (2012). New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut, 61(suppl 1), i36–i46.
Food and Drug Administration. (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74, 65132–65133.
Guest, G., Bunce, A., & Johnson, L. (2006). How many interviews are enough? An experiment with data saturation and variability. Field Methods, 18(1), 59–82.
Shumaker, S. A., Berzon, R., & Hays, R. (Eds.). (1993). Special issue. International use, application and performance of health-related quality of life instruments. Quality of Life Research, 2(6), 367–368.
Brod, M., Tesler, L. E., & Christensen, T. L. (2009). Qualitative research and content validity: Developing best practices based on science and experience. Quality of Life Research, 18, 1263–1278.
Ware, J. E, Jr, Kosinski, M., Bjorner, J. B., Turner-Bowker, D. M., Gandek, B., & Maruish, M. E. (2007). User’s manual for the SF-36v2 health survey (2nd ed.). Lincoln: Quality Metric Incorporated.
Cantril, H. (1965). The pattern of human concerns. New Brubswick: Rutgers University Press.
Spiegel, B. M., Younossi, Z. M., Hays, R. D., Revicki, D., Robbins, S., & Kanwal, F. (2005). Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology, 41, 790–800.
Hollander, A., Foster, G. R., & Weiland, O. (2006). Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology, 41(5), 577–585.
Bernstein, D., Kleinman, L., Barker, C. M., Revicki, D. A., & Green, J. (2002). Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology (Baltimore, Md.), 35(3), 704–708.
Mathews, A., Peiffer, L. P., Rhoades, K., & McGarrity, T. J. (2006). Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin. Health and Quality of Life Outcomes, 4, 30.
Kang, S.-C., Hwang, S.-J., Lee, S.-H., Chang, F.-Y., & Lee, S.-D. (2005). Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World Journal of Gastroenterology: WJG, 11(47), 7494–7498.
Hassanein, T., Cooksley, G., Sulkowski, M., et al. (2004). The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. Journal of Hepatology, 40(4), 675–681.
Nunnally, J. C., & Berstain, I. H. (1994). Psychometric theory (3rd ed.). New York: McGraw-Hill.
Wiggins, J. S. (1973). Personality and prediction: Principles of personality assessment. Reading, MA: Addison-Wesley.
MacCallum, R. (1986). Specification searches in covariance structure analysis. Psychological Bulletin, 100, 107–210.
Bentler, P., & Bonnett, D. (1980). Significance tests and goodness of fit in the analysis of covariance structures. Psychological Bulletin, 88, 588–606.
Bentler, P. (1990). Comparative fit indices in structural models. Psychological Bulletin, 107, 238–246.
Bonkovsky, H. L., & Woolley, J. M. (1999). Consensus interferon study group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology, 29, 264–270.
Gralnek, I. M., Hays, R. D., Kilbourne, A., Rosen, H. R., Keeffe, E. B., Artinian, L., et al. (2000). Development and evaluation of the liver disease quality of life instrument in persons with advanced, chronic liver disease: The LDQOL 1.0. American Journal of Gastroenterology, 95(12), 3552–3565.
Shumaker, S. A., Anderson, R. T., & Czajkowski, S. M. (1990). Psychological tests and scales. In B. Spilker (Ed.), Quality of life assessments in clinical trials (pp. 95–114). New York: Raven Press.
Kleinman, L., Mannix, S., Yuan, Y., Kummer, S., L’Italien, G., & Revicki, D. (2012). Review of patient-reported outcome measures in chronic hepatits C. Health and Quality of Life Outcomes, 10, 92.
Acknowledgments
Medical writing and editing services were provided by Amanda Perry, BA Palmyra PA, and Fabian Camacho MS Hershey PA for statistical support. Medical writing support was funded by Abbott Laboratories Inc., Abbott Park, Illinois.
Author information
Authors and Affiliations
Corresponding author
Additional information
All rights for the HCV-PRO reside with Abbott Laboratories.
Rights and permissions
About this article
Cite this article
Anderson, R.T., Baran, R.W., Dietz, B. et al. Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument. Qual Life Res 23, 561–570 (2014). https://doi.org/10.1007/s11136-013-0505-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-013-0505-7